Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above

To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.

NCT Number	NCT07481604
Lead Sponsor	CHA Vaccine Institute Co., Ltd.
Conditions	Herpes Zoster
Enrollment	135 participants
Start Date	2026-04
Primary Completion	2027-01 (estimated)
Study Completion	2027-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-19